About SIRTURO®
SIRTURO® (bedaquiline) Is a First-in-Class ATP Synthase Inhibitor for Pulmonary Multi-drug Resistant TB (MDR-TB)
SIRTURO® adds a novel mechanism of action to the treatment of pulmonary MDR-TB.
- SIRTURO® is the first anti-TB drug to interfere with bacterial energy
metabolism.5-7 It is
mechanistically and structurally unrelated to current first-line agents.2,5,7,8
- SIRTURO® specifically inhibits mycobacterial ATP (adenosine
5’-triphosphate) synthase, by binding to subunit c of the enzyme that is essential for the
generation of energy in Mycobacterium tuberculosis.

Download a comprehensive resource on SIRTURO® (bedaquiline)
tablets